Furthermore, a bioinformatic study defining the RRM2 signature in PCa suggested that the RRM2 signature may predict enzalutamide resistance, and RRM2 overexpression suggests an immunosuppressive tumor microenvironment in prostate cancer [52], indicating that RRM2 may be implicated in the therapeutic resistance of ADT and immunotherapy. Here, RRM2 is linked to neoplasm.